Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant비활성화 기반 COVID-19 백신의 3회 용량은 SARS CoV-2 Omicron 변이체에 대한 교차 중화 면역을 유도합니다Coronaviruses Published on 2022-03-032022-09-10 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 B.1.1.529 collected coronavirus COVID-19 vaccine cross-neutralizing delta variant demonstrated dose enrolled fold geometric mean geometric mean titer geometric mean titers GMT immune Immunity immunization immunized induce natural infection neutralization activity Neutralizing activity neutralizing antibody omicron Omicron variant positive prototype pseudotyped Pseudotyped virus recipient reported respiratory SARS CoV SARS CoV-2 SARS-CoV-2 sera serum sample serum samples severe acute respiratory syndrome Coronavirus sustained the vaccine vaccination Vaccine variant was determined [DOI] 10.1080/22221751.2022.2044271 PMC 바로가기 [Article Type] Coronaviruses
Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients비활성화된 SARS-CoV-2 백신의 추가 접종 전 운동 시합이 면역 저하 환자의 면역원성에 미치는 영향Randomized Controlled Trial Published on 2022-03-012022-09-12 Journal: Journal of applied physiology (Bethesda, Md. : 198 [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] anti-SARS-CoV-2 assigned booster booster dose comparable consecutive patient control group COVID-19 COVID-19 vaccine Effect ENhance exercise exhibited Frequency geometric mean titer GMT group homologous IgG immunized Immunocompromised patient immunogenicity Immunosuppression in both groups inactivated Inactivated vaccine intervention group NAb activity Neutralizing antibodies neutralizing antibody occurred Patient performed physical physical activity positive randomized controlled study remained resistance exercise resistance exercise. S1/S2 SARS-CoV-2 SARS-CoV-2 vaccine selected serology Sinovac-CoronaVac spondyloarthritis tested the vaccine vaccination [DOI] 10.1152/japplphysiol.00015.2022 PMC 바로가기 [Article Type] Randomized Controlled Trial
Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseasesClinical Trial Published on 2022-03-012022-10-05 Journal: Brain, behavior, and immunity [Category] SARS, 임상, [키워드] anti-SARS-CoV-2 ARD ARD patient ARD patients Autoimmune benefit cluster analysis coronavirus covariates defined ENhance exercise exhibited Frequency geometric mean titer GMT greater IgG Immunocompromised patients immunogenicity inactivated Inactivated vaccine inactive individual less lifestyle median Neutralizing activity neutralizing antibody Open-label Patient physical physical activity physically prospective cohort study questionnaire rheumatic disease S1/S2 SARS-CoV-2 SARS-CoV-2 vaccine Sedentary behavior seroconversion rate single-arm Trial vaccination Vaccine virus were assessed [DOI] 10.1016/j.bbi.2021.12.016 PMC 바로가기 [Article Type] Clinical Trial
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination동종 및 이종 CoronaVac 또는 BNT162b2 백신 접종 후 SARS-CoV-2 Omicron 변이체 BA.1에 대한 중화 항체Article Published on 2022-03-012022-09-11 Journal: Nature Medicine [Category] SARS, 변종, 진단, [키워드] antibody Antibody titer BNT162b2 booster booster dose circulating convalescent CoronaVac country dominant dose Effectiveness elicited geometric mean geometric mean titer GMT Heterologous homologous individual infected individual Infection Live virus Messenger RNA Neutralizing activity of BNT162b2 omicron Omicron variant plaque plaque reduction neutralization PRNT reduced reductions reductions in SARS-CoV-2 SARS-CoV-2 virus serum serum antibody Spread the SARS-CoV-2 threshold to define vaccinated individual vaccinated individuals vaccination Vaccine variant virus wild-type WT virus [DOI] 10.1038/s41591-022-01704-7 PMC 바로가기 [Article Type] Article
Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern프로토타입 SARS-CoV-2 비활성화 백신의 3회 용량은 우려되는 변이체에 대한 교차 보호를 유도합니다Article Published on 2022-02-252022-09-10 Journal: Signal Transduction and Targeted Therapy [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Alpha anal swabs Beta COVID-19 cross-protection Delta dose evaluate Experimental models of disease extension followed by geometric mean geometric mean titer GMT in vivo Inactivated vaccine induce Infectious diseases lung nasal Neutralizing antibodies neutralizing antibody omicron Omicron variants pandemic pathological change pathological changes Prevention and control produced reduced Rhesus monkey Rhesus monkeys SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant tissues Vaccine variant variants variants of concern Viral Viral load viral loads VoC VOCs [DOI] 10.1038/s41392-022-00920-4 PMC 바로가기 [Article Type] Article
Sequentially immune-induced antibodies could cross-neutralize SARS-CoV-2 variants순차적으로 면역 유도된 항체는 SARS-CoV-2 변이체를 교차 중화할 수 있습니다Article Published on 2022-02-012022-09-11 Journal: Animal models and experimental medicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] antibody B.1.1.529 collected cross-neutralize cross-neutralize SARS-CoV-2 cross-neutralizing delta variant Delta variants demonstrated dose geometric mean geometric mean titer geometric mean titers GMT GMTs Human human sera Humoral immunity immune Immunity in vitro inactivated Inactivated vaccine lead Mutation neutralization Neutralization antibody neutralization titers Neutralizing activity neutralizing antibody omicron Omicron variant PiCoVacc Protein raised Recombinant protein reduction in SARS-CoV-2 SARS-CoV-2 variant sequentially immune. sera Spike protein target the spike protein vaccination Vaccine variant wild type ZF2001 [DOI] 10.1002/ame2.12216 PMC 바로가기 [Article Type] Article
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial Research Published on 2022-01-272022-10-05 Journal: Nature Medicine [Category] COVID19(2023년), SARS, 임상, [키워드] acute respiratory syndrome Adverse reaction booster booster vaccination co-primary endpoint CoronaVac coronavirus coronavirus disease COVID-19 COVID-19 vaccine dose elicited evaluated generally mild geometric mean titer GMT GMTs Heterologous homologous immunogenic individual initial moderate neutralizing antibody observer-blinded Occurrence participant Randomized recipient recombinant adenovirus Safe SARS-CoV-2 significantly increased significantly more treatment groups Trial vaccination vaccine dose variant virus wild-type SARS-CoV-2 [DOI] 10.1038/s41591-021-01677-z [Article Type] Research
Monitoring of SARS-CoV-2 Specific Antibodies after VaccinationArticle Published on 2022-01-202022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] 95% CI age analyzed antibody Antibody titer baseline binding Chronic diseases Cohort collected correlated correlation COVID-19 COVID-19 pandemic decrease detect Effectiveness ELISA assay Extensive follow-up study geometric mean titer groups HCW Health care worker health care workers IgG immune response immunology monitoring NAb Neutralizing Neutralizing antibodies neutralizing antibody Population Portugal promote recruitment required robust Sample SARS-CoV-2 SARS-COV-2 infection second dose serum sample Sex significant decrease significant difference significantly higher Specific vaccinated individuals vaccination Vaccine vaccine dose [DOI] 10.3390/vaccines10020154 PMC 바로가기 [Article Type] Article
Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodiesCoronaVac 백신 유도 항체에 의한 알파, 감마 및 D614G SARS-CoV-2 변이체 중화Article Published on 2022-01-012022-09-11 Journal: Journal of medical virology [Category] SARS, 변종, 진단, 치료기술, 치료제, [키워드] Alpha analyzed antibody collected CoronaVac CoronaVac vaccine Cytopathic effect D614G develop dose Effective strategies effective strategy efficient elicited generate genomic Genomic surveillance geometric mean geometric mean titer GMT help immune response inactivated individual Mutation neutralization neutralization potency Neutralizing Neutralizing antibodies plasma plasma samples reduction SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants second dose Surveillance vaccination Vaccine vaccine-induced antibody variant variants variants of SARS-CoV-2 Vero E6 Vero E6 cell VERO E6 cells Viral viral variant Viral variants [DOI] 10.1002/jmv.27310 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial고위험 직업군에서 비활성화된 SARS-CoV-2 백신의 안전성 및 면역원성: 무작위, 병렬, 대조 임상 시험Randomized Controlled Trial Published on 2021-12-222022-09-12 Journal: Infectious Diseases of Poverty [Category] Coronavirus, SARS, 임상, 진단, [키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus Adverse reaction Adverse reactions Analysis ANOVA antibody assigned baseline Chi-square China Chinese city clinical collected Controlled clinical trial Controlled trial coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Data analysis determine dose Endpoint geometric mean geometric mean titer GMT health-care system High-risk occupational population immunization immunogenicity inactivated Inactivated SARS-CoV-2 vaccine Infection injection Injections intention-to-treat ITT live SARS-CoV-2 Logistic regression analysis Mild neutralization Neutralizing antibodies neutralizing antibody participant primary immunogenicity randomization Randomized Randomized controlled trial Randomly receive regimen registry reported Result resulting Safety SARS-CoV-2 SARS-CoV-2 neutralizing antibody SARS-CoV-2 vaccine second dose Seroconversion seroconversion rate seroconversion rates Serum neutralizing antibody severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 significantly significantly lower supplementary material the vaccine three groups Trial vaccination variance was performed were used [DOI] 10.1186/s40249-021-00924-2 PMC 바로가기 [Article Type] Randomized Controlled Trial